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HIV-1 Tat and cocaine mediated
synaptopathy in cortical and
midbrain neurons is prevented by the
isoflavone Equol
Sarah J. Bertrand, Calvin Hu, Marina V. Aksenova, Charles F. Mactutus and
Rosemarie M. Booze*
Laboratory Program in Behavioral Neuroscience, Department of Psychology, University of South Carolina, Columbia,
SC, USA
Illicit drugs, such as cocaine, are known to increase the likelihood and severity of HIV-
1 associated neurocognitive disorders (HAND). In the current studies synaptic integrity
was assessed following exposure to low concentrations of the HIV-1 viral protein Tat
1-86B, with or without cocaine, by quantifying filamentous actin (F-actin) rich structures
(i.e., puncta and dendritic spines) on neuronal dendrites in vitro. In addition, the synapse-
protective effects of either R-Equol (RE) or S-Equol (SE; derivatives of the soy isoflavone,
daidzein) were determined. Individually, neither low concentrations of HIV-1 Tat (10 nM)
nor low concentrations of cocaine (1.6 μM) had any significant effect on F-actin puncta
number; however, the same low concentrations of HIV-1 Tat + cocaine in combination
significantly reduced dendritic synapses. This synaptic reduction was prevented by
pre-treatment with either RE or SE, in an estrogen receptor beta dependent manner.
In sum, targeted therapeutic intervention with SE may prevent HIV-1 + drug abuse
synaptopathy, and thereby potentially influence the development of HAND.
Keywords: soy isoflavone, F-actin, S-Equol, estrogen receptor, HAND
Introduction
Cocaine abuse signiﬁcantly increases the risk of HIV-1 transmission. HIV-1+ individuals that use
cocaine progress from HIV-1 infection to AIDS more quickly (Baum et al., 2009), are more likely
to develop neurocognitive disorders (Levine et al., 2006; Nath, 2010), and display an accelerated
progression of HIV-1 associated neurocognitive disorders (HAND; Nath, 2010). Neurocognitive
dysfunction and drug abuse are two of the most common factors for medication non-compliance
in treatment of HIV-1 (Panos et al., 2014), and therefore HIV-1 positive drug abusers with
neurocognitive disorders have a higher risk for disease progression, increased mortality rates, and
a lower quality of life (Wisniewski et al., 2005; Cook et al., 2007; Baum et al., 2009; Doshi et al.,
2012; Qian et al., 2014).
Eﬀective combined anti-retroviral therapy (cART) suppresses viral replication. However,
infected astrocytes and microglia may continue to release HIV-1 proteins (i.e., Tat), into the
extracellular space (Nath, 2010; Desplats et al., 2013). The released HIV-1 Tat proteins may then
interact with neurons to produce dysfunction (Moore et al., 2006; Chang et al., 2008; Gongvatana
et al., 2011; Desplats et al., 2013; Ortega et al., 2015). Exposure to the HIV-1 Tat protein produces
loss of F-actin prior to cell death (Bertrand et al., 2013, 2014). HIV-1 Tat protein increases actin
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depolymerization (Wu et al., 2004) and HIV-1 Tat protein
alters NMDA receptor calcium currents via interactions with
the actin cytoskeleton (Krogh et al., 2015). The HIV-1 Tat
induced loss of F-actin may be a reversible process, mediated by
stimulation of estrogen receptors (Bertrand et al., 2014). Thus,
F-actin dysregulation may play a key role in HIV-1 induced
synaptodendritic damage and synaptopathy.
Pre- and post-synaptic neuronal structures are rich in actin,
a dynamic cytoskeletal protein (Zhang and Benson, 2001;
Johnson and Ouimet, 2006; Sekino et al., 2007; Hotulainen
et al., 2009). Subsequent to cellular signaling, globular actin (G-
actin) is polymerized into ﬁlamentous actin (F-actin), resulting
in a stable synaptic structure (Johnson and Ouimet, 2006;
Sekino et al., 2007; Hotulainen et al., 2009). Stabilized synaptic
structures are rich in F-actin and appear as punctate dendritic
structures (Bertrand et al., 2014); these F-actin neuronal
structures may be either protruding mature dendritic spines,
early stages of developing dendritic spines (patches; Matus
et al., 1982; Johnson and Ouimet, 2006; Sekino et al., 2007;
Hotulainen et al., 2009), non-spiny or inhibitory synapses
(Heller et al., 2012), or pre-synaptic structures (Halpain,
2003; Sankaranarayanan et al., 2003). Since F-actin puncta
encompass a variety of synaptic structures (Halpain, 2003;
Sankaranarayanan et al., 2003) decreased F-actin puncta indicates
a synaptopathy in which synaptic response and connectivity is
globally diminished.
HIV-1 transgenic rats have abnormally short and stubby
dendritic spines (Roscoe et al., 2014). Similarly, tat protein
transgenic mice show decreased spine density (Fitting et al.,
2015). HIV-1 infected cells have signiﬁcantly decreased spine
density, spine length, spine area, and spine number in
comparison to uninfected control cells (Kurapati et al., 2013)
and increased HIV-1 cell death in combination with cocaine
(Kurapati et al., 2014). Conversely, chronic cocaine exposure
in rats increased the expression of F-actin (Kalivas, 2009)
and increases dendritic spine density (Martin et al., 2011).
Actively inhibiting the polymerization of G-actin into F-actin
prevents spine morphological changes found in the nucleus
accumbens of rats acutely treated with cocaine (Toda et al.,
2010). Although it is clear that both HIV-1 Tat protein and
cocaine alter dendritic spines, the combined eﬀects of HIV-1
Tat and cocaine on F-actin containing synapses have not been
investigated.
Phytoestrogens are naturally occurring compounds that are
structurally similar to 17β-estradiol (Glazier and Bowman, 2001;
Lephart et al., 2005). The soy-derived phytoestrogen daidzein
prevents HIV-1 Tat induced neuronal apoptosis (Adams et al.,
2012) and synaptodendritic injury caused by HIV-1 Tat (Bertrand
et al., 2014). Daidzein is initially metabolized in the gut
into dihydrodaidzein, which is further metabolized into either
O-desmethylangolensin or cis/trans-isoﬂavan-4-ol (Lampe, 2009;
Jackson et al., 2011). Finally, cis/trans-isoﬂavn-4-ol is processed
into S-Equol (SE). Due to the chiral center at carbon 3, equol
can exist in either the S or R conformation; however, only
SE is produced by humans and animals (Setchell et al., 2005).
Equol aﬀects neuronal mitochondrial function (Yao et al., 2013)
and hypothalamic neuronal expression (Patisaul et al., 2009) in
vivo, suggesting that equol can cross the blood–brain barrier at
physiological concentrations.
HIV-1+ cocaine abusers are more likely to display
neurocognitive deﬁcits relative to non-drug abusers (Levine
et al., 2006; Nath, 2010); however, the mechanism producing
these neurocognitive deﬁcits is unclear. HIV-1 viral infection in
the presence of cocaine has been shown to cause cell death in
vitro (Kurapati et al., 2013, 2014). HIV-1 Tat protein + cocaine
has been reported to produce enhanced levels of apoptosis
(Kendall et al., 2005). In contrast, the eﬀects of HIV-1 Tat
proteins + cocaine on synapses are unknown. The present study
uses the quantiﬁcation of F-actin puncta, a marker of dendritic
synapses, to evaluate the eﬀects of HIV-1 Tat and cocaine.
Additionally, we evaluated the estrogen receptor-mediated
mechanisms of both SE and R-Equol neuroprotection. Our
results suggest that HIV-1 Tat and cocaine together produce
enhanced synaptodendritic injury, resulting in a synaptopathy
that may contribute to the increased incidence of neurocognitive
disorders in HIV-1+ cocaine users. S- and R-Equol (RE)
treatment may prevent this synaptopathy via speciﬁc estrogen
receptors.
Materials and Methods
Ethics Statement
Experiments were in accordance with NIH Guidelines. The
Institutional Animal Care and Use Committee at the University
of South Carolina (assurance number: A3049-01) reviewed and
approved all animal usage.
Primary Neuronal Cell Culture
Cortical and midbrain regions were dissected from gestational
day 18 Sprague-Dawley rat fetuses (Harlan Laboratories,
Indianapolis, IN, USA) as previously described (Aksenova et al.,
2006, 2009; Bertrand et al., 2011; for protocol see Li et al.,
2015). Following dissection, brain tissue was incubated in a
solution of 2 mg/ml trypsin in Hank’s balanced salt solution
(HBSS) buﬀered with 10 mMHEPES (GIBCO Life Technologies,
Grand Island, NY, USA) for 10 min. Tissue was rinsed with
fresh HBSS three times and then exposed to soybean trypsin
inhibitor (1 mg/ml in HBSS) for 2 min. Tissue was washed
three times with HBSS following trypsin inhibitor treatment. For
cytomorphological studies, cells were distributed to 12 well glass-
bottom dishes and 35 mm dishes (MatTek Corporation, Ashland,
MA, USA) coated with poly-L-lysine following dissociation
by trituration. In order to observe distinct second order
branching patterns, a low plating density was used (120–140
cells/mm2). Initial plating media contained Dulbecco’s modiﬁed
Eagle’s medium/Ham’s nutrient mixture F-12 (DMEM/F12;
GIBCO) supplemented with 100 ml/L fetal bovine serum (Sigma
Chemicals, St. Louis, MO, USA). DMEM/F12 and fetal serum
were removed and replaced with an equal amount of serum-
free Neurobasal medium after 24 h. Neurobasal medium had
no phenol red and was supplemented with 2% v/v B-27,
2 mM GlutaMAX supplement and 0.5% w/v D-(1) glucose (all
ingredients from GIBCO). Cultures were maintained at 37◦C
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in a 5% CO2/95% room air-humidiﬁed incubator at all times.
Fresh Neurobasal medium was supplemented at weekly intervals.
Midbrain cultures used for experiments were 21–30 days in
vitro (DIV), cortical cultures were used for experiments at
14–21 DIV, cell cultures from both regions were >85–90%
neuronal as determined by MAP-2/GFAP/NucBlue ﬂuorescent
staining.
Experimental Drug Treatments
Recombinant Tat 1-86B (LAI/Bru strain of HIV-1 clade B,
GenBank accession no. K02013; Diatheva, Fano, Italy) was added
to the serum free growth media (10 or 50 nMﬁnal concentration).
In experiments where cocaine was included, freshly prepared
cocaine solution (1.6 μM ﬁnal concentration) was added to the
serum free grown media concurrently with HIV-1 Tat 1–86B
treatment. The 1.6 μM concentration of cocaine in the cultures
reﬂects levels found in the arterial blood supply to the brain
following IV cocaine administration in humans (Evans et al.,
1996) and rats (Mactutus et al., 1994; Booze et al., 1997), thus
representing a physiologically relevant concentration of cocaine.
This cocaine concentration has been used in our previous studies
(Kendall et al., 2005; Aksenov et al., 2006, 2008), and is well
below the neurotoxic levels of cocaine (100 μM; Bennett et al.,
1993). The low concentration of S- and RE (33 nM), as well
as the mid-range concentration of S- and RE (50 nM) used in
these studies, are similar to plasma concentrations observed in
humans following supplementation (8 and 12 ng/ml, respectively;
Jackson et al., 2011). Control cultures were treated with an
equivalent volume of vehicle. Cultures were incubated with
either 50 nM HIV-1 Tat, 10 nM HIV-1 Tat, 1.6 μM cocaine,
or HIV-1 Tat(10 nM) + cocaine(1.6 μM) for 24 h prior to
ﬁxation.
Cortical and midbrain cell cultures were treated with either
SE (ﬁnal concentration 33 or 50 nM; ≥98.5% purity; Cayman
Chemical, Ann Arbor, MI, USA), RE (ﬁnal concentration
33 or 50 nM; ≥98.5% purity; Cayman Chemical Ann Arbor,
MI, USA), or tamoxifen (TMX; selective estrogen receptor
antagonist; ﬁnal concentration 100 nM; TMX citrate; Tocris
Bioscience, Ellisville, MD). For the neuroprotection studies,
cells were treated with either SE or RE (33 or 50 nM)
for 24 h prior to treatment with either 50 nM HIV-1
Tat or 10 nM HIV-1 Tat + 1.6 μM cocaine. In order to
determine which estrogenic receptors were necessary for
SE and RE neuroprotection, cells were treated with TMX
for 1 h prior to treatment with either SE (50 nM), RE
(50 nM), 4-[2-Phenyl-5,7-bis(triﬂuoromethyl)pyrazolo[1,5-
a]pyrmidin-3-yl)phenol (PHTPP) estrogen receptor beta
(ERβ) antagonist, ﬁnal concentration 100 nM (Tocris
Bioscience, Ellisville, MD, USA); 1,3-Bis(4-hydroxyphenyl)-
4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole
dihydrochloride (MPP) estrogen receptor alpha antagonist;
ﬁnal concentration 100 nM (Tocris Bioscience, Ellisville, MD,
USA), or (3aS∗,4R∗,9bR∗)-4-(6-Bromo-1,3-benzodioxol-5-
yl)-3a,4,5,9b-3H-cyclopenta[c]quinoline (G15) membrane
estrogen receptor antagonist, ﬁnal concentration 100 nM
(Tocris Bioscience, Ellisville, MD, USA). TMX, PHTPP, G15,
SE, and RE were initially dissolved in DMSO and then diluted
in PBS prior to treatment. MPP was initially dissolved in
distilled water, and diluted immediately prior to treatment.
For neuroprotection studies, cells were treated with either SE
or RE (33 or 50 nM) for 24 h prior to treatment with 50 nM
Tat or 10 nM Tat and 1.6 μM cocaine. In order to determine
which of the speciﬁc estrogen receptor subtypes might underlie
SE and RE neuroprotection, cells were treated with TMX,
PHTPP, MPP, or G15 for 1 h prior to treatment with SE or RE
(50 nM).
Fluorescent Staining and
Immunocytochemistry
A previously described method (Bertrand et al., 2013; for
detailed protocol see Li et al., 2015) for F-actin staining
was used to visualize F-actin puncta localized on neuronal
dendrites. Brieﬂy, primary neuronal cultures were ﬁxed
using 4% paraformaldehyde and permeabilized with 0.1%
Triton X-100. Cells were incubated with the F-actin
speciﬁc probe, phalloidin (1:40; AlexaFluor 488), for
20 min (Invitrogen Life Technologies, Grand Island, NY,
USA).
Following staining for F-actin, cultures were treated with 10%
normal horse serum in PBS for 2 h. Neurons were co-labeled
with chicken polyclonal anti-MAP2 antibodies (1:1000; Abcam,
Cambridge, MA, USA). Goat anti-chicken IgG conjugated with
Alexa Red 594 (1:500; Invitrogen Life Technologies, Grand
Island, NY, USA) was used as a secondary antibody to
identify MAP2-positive dendrites. NucBlue (Molecular Probes
Life Technologies, Grand Island, NY, USA), a Hoescht dye, was
added directly to the cultures to identify cell nuclei (Bertrand
et al., 2014).
A Nikon Eclipse TE2000-E inverted ﬂuorescent microscope
(20X objective, 1600 × 1200 px image size, 0.17 μm/px
image resolution at 1X zoom) and a high resolution CCD
camera was used to obtain images of neurons co-labeled with
F-actin/MAP-2/NucBlue. The NIS-Elements software package
(Nikon Instruments, Melville, NY, USA) was used to analyze 3–
5 separate neurons per culture well. All imaged neurons had
clearly identiﬁable complete dendritic arbors and normal nuclear
morphology. F-actin puncta were identiﬁed in several (3–4)
second order dendritic segments (15–75 μm) for each neuron.
For inclusion, dendrites were required to have continuous MAP-
2 positive immunoﬂuorescence co-localized with Phalloidin
staining. Phalloidin-labeled structures included ﬁne ﬁlopodia,
spine protrusions, and patches. Growth cones (F-actin rich
structures at the distal end of dendrites) were excluded (Bertrand
et al., 2013).
F-actin puncta were quantiﬁed as previously described
(Bertrand et al., 2013, 2014). Brieﬂy, background ﬂuorescence
from the 488 (green phalloidin labeled F-actin) channel was
subtracted, identiﬁed as low ﬂuorescence of the non-synaptic
dendritic shaft (20–50 au). Bright F-actin rich structures on
the dendrite (ﬁne ﬁlopodia, spine protrusions, and patches)
were manually counted. The number of F-actin puncta per
10 μm of dendrite was reported by two trained independent
observers. These investigators, blinded to experimental
treatment, quantiﬁed puncta from identically processed
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images, with a very high correlation (r2 = 0.90), indicating
that the bright green F-actin puncta on dendrites were readily
identiﬁed.
Statistical Analysis
Statistical comparisons were made using ANOVA techniques,
and Tukey’s multiple comparison tests were used to determine
speciﬁc treatment eﬀects. Pearson’s product-moment correlation
coeﬃcient was calculated to verify inter-rater reliability.
Comparisons and correlations were calculated using SPSS
version 22 (IBM Corporation, Armonk, NY, USA). Data
represents mean values ± SEM. Signiﬁcant diﬀerences were set
at p ≤ 0.05.
Results
S-Equol and R-Equol Prevent HIV-1 Tat
Induced Synapse Loss
Midbrain neurons were pre-treated with either RE (33 or 50 nM)
or SE (33 or 50 nM) for 24 h prior to 50 nM HIV-1 Tat
(Figure 1). There was a signiﬁcant main eﬀect of treatment
F(1,22) = 9.4, p ≤ 0.001, with 50 nM HIV-1 Tat producing
a signiﬁcant reduction in F-actin puncta (p ≤ 0.001). Pre-
treatment with 50 nM RE (p ≤ 0.01), but not 33 nM RE,
prevented signiﬁcant loss of F-actin puncta following 50 nM
HIV-1 Tat (Figure 1B). Pre-treatment with either 33 nM SE
(p ≤ 0.05) or 50 nM SE (p ≤ 0.001) prevented HIV-1 Tat
induced loss of F-actin puncta (Figure 1C). RE and SE treatment
alone did not produce either signiﬁcant loss or proliferation of
F-actin puncta (Figures 1B,C). RE or SE pre-treated HIV-1 Tat
(50 nM) neurons were not statistically diﬀerent from vehicle-
treated neurons.
S-Equol and R-Equol Act Through an Estrogen
Mediated Mechanism to Prevent HIV-1 Tat
Induced Synapse Loss
The neuroprotective mechanisms of RE and SE in midbrain
neurons against HIV-1 Tat induced synapse loss were determined
by pre-treatment with TMX, a potent estrogen receptor
antagonist. TMX was added to the cultures 1 h prior to the
addition of either SE or RE. Cultures were then incubated with
HIV-1 Tat 1–86 (50 nM) for 24 h. Pre-treatment with TMX prior
to SE (p ≤ 0.02) and RE (p ≤ 0.02) resulted in signiﬁcant loss of
F-actin puncta relative to control cultures. These F-actin losses
were not signiﬁcantly diﬀerent from cultures treated with HIV-1
Tat (50 nM) alone, suggesting that RE and SE act through an ER
dependent mechanism (Figure 1D).
HIV-1 Tat and Cocaine Interact to Produce
Synaptopathy in Midbrain and Cortical
Neurons
In order to examine the eﬀects of HIV-1 Tat and cocaine
on F-actin puncta, a low dose of HIV-1 Tat 1–86 (10 nM)
and a physiologically relevant dose of cocaine (1.6 μM) were
FIGURE 1 | R-Equol (RE) and S-Equol (SE) prevented synaptic loss induced by HIV-1 Tat (50 nM) via an estrogen receptor mediated mechanism.
(A) Conversion of the soy isoflavone daidzein to SE. The dotted circle identifies a chiral center on carbon 3 wherein a conformational change produces RE. However,
only SE may be produced by mammalian gut bacteria. (B) A moderate concentration of RE (50 nM), but not a low concentration (33 nM), prevented significant
F-actin puncta loss induced by HIV-1 Tat (50 nM; p ≤ 0.01). (C) Both the low (33 nM) and moderate (50 nM) concentrations of SE prevented HIV-1 Tat induced
F-actin puncta loss (p ≤ 0.05 and p ≤ 0.001, respectively). (D) 1 h pre-treatment with TMX (100 nM) blocked the protective effects of RE and SE (50 nM) against
HIV-1 Tat (50 nM) in midbrain neurons. Mean ± SEM, ∗p ≤ 0.05 compared to HIV-1 Tat treatment.
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FIGURE 2 | HIV-1 Tat (10 nM) + cocaine (1.6 μM) treatment produced significant synaptic loss in midbrain and cortical neurons, which was
prevented by pre-treatment with either RE or SE. (A) Treatment with either SE, RE, HIV-1 Tat, or cocaine does not significantly alter the density of
dendritic F-actin puncta compared to controls in midbrain neurons. Treatment with HIV-1 Tat + cocaine produced significant loss of F-actin puncta (p ≤ 0.05).
(B) Treatment with either SE, RE, HIV-1 Tat, or cocaine does not significantly alter the density of dendritic F-actin puncta compared to controls in cortical
neurons. Treatment with HIV-1 Tat + cocaine produced significant loss of F-actin puncta (p ≤ 0.05). (C) Pre-treatment with either RE or SE (50 nM) prevented
dendritic F-actin puncta loss caused by HIV-1 Tat + cocaine treatments in midbrain neurons. Dendrites from pre-treated neurons are not significantly different
from vehicle-treated controls (mean values, dotted line). (D) Pre-treatment with either RE or SE (50 nM) prevents HIV-1Tat + cocaine induced loss of dendritic
F-actin puncta (p ≤ 0.001) in cortical neurons. Dendrites from pre-treated neurons are not significantly different from vehicle-treated controls (mean values,
dotted line). (E) Pre-treatment of midbrain neurons with TMX (100 nM) for 1 h prior to either RE or SE prevented the protective effects of RE and SE,
suggesting an estrogen receptor mediated mechanism. Vehicle-treated control mean values are represented by dotted line. (F) Pre-treatment of cortical neurons
with TMX (100 nM) for 1 h prior to either RE or SE prevented the protective effects of RE and SE, suggesting an estrogen receptor mediated mechanism.
Control mean value represented by dotted line. Mean ± SEM, ∗p ≤ 0.05 compared either to vehicle-treated controls (A,B) or HIV-1 Tat + cocaine (C,D).
simultaneously added to the cultures and incubated for 24 h.
As shown in Figures 2A,B, there was a signiﬁcant eﬀect of
HIV-1 Tat + cocaine F(1,123) = 16.4, (p ≤ 0.001) but no
signiﬁcant eﬀect of either HIV-1 Tat or cocaine individually on
dendritic F-actin puncta. Neurons cultured from fetal cortical
and midbrain regions responded to HIV-1 Tat + cocaine
similarly, as there were no signiﬁcant diﬀerences between the
brain region cultured F(1,123) = 3.4, p> 0.05.
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S-Equol and R-Equol Prevent Interactive HIV-1
Tat + Cocaine Synaptopathy
Cortical and midbrain neurons were pre-treated with either
50 nM RE or SE for 24 h prior to HIV-1 Tat (10 nM) + cocaine
(1.6 μM). There was a signiﬁcant main eﬀect of treatment
F(5,123) = 7.6, p ≤ 0.001 (Figures 2C,D), but not a signiﬁcant
eﬀect of brain region (p > 0.05). Using a Tukey post hoc
analysis it was determined that HIV-1Tat + cocaine neurons
pretreated with either RE or SE had signiﬁcantly more dendritic
F-actin puncta relative to HIV-1 Tat + cocaine treated neurons
(p ≤ 0.001). The number of puncta on RE and SE pre-treated
neurons and were not signiﬁcantly diﬀerent from vehicle-treated
controls.
S-Equol and R-Equol Prevent HIV-1
Tat + Cocaine Induced Synaptopathy via an
ERβ Mechanism
Primary cortical and midbrain cultures were treated with TMX,
an estrogen receptor antagonist, for 1 h prior to treatment with
RE or SE. Following a 24 h incubation with HIV-1 Tat + cocaine,
F-actin puncta were assessed. TMX pre-treatment prevented both
RE and SE mediated synaptic protection following HIV-1 Tat +
cocaine (p ≤ 0.01; Figures 2E,F).
Cortical neurons were treated with one of three selective ER
subtype antagonists, MPP (ERα), PHTPP (ERβ), or G15 (GPR30)
for 1 h prior to treatment with RE or SE in order to identify
the speciﬁc ER subtype required for equol-mediated synaptic
protection following HIV-1 Tat + cocaine (Figures 3A,B).
There was a signiﬁcant main eﬀect of antagonist treatment
F(3,134) = 11.2, p ≤ 0.001. Further analysis revealed that
both the MPP, as well as the G15, treated dendrites were not
signiﬁcantly diﬀerent from vehicle-treated controls (p > 0.05);
however, PHTPP-treated dendrites had a signiﬁcant loss of
F-actin puncta when compared to controls (p ≤ 0.05) and
were not signiﬁcantly diﬀerent from HIV-1 Tat + cocaine
treated dendtrites (p > 0.05). More speciﬁcally, only the
ERβ antagonist PHTPP signiﬁcantly prevented RE or SE
mediated synaptic protection (p ≤ 0.001), indicative of an
ERβ dependent mechanism. Examination of either vehicle
(Figure 3C), HIV-1 Tat (10 nM; Figure 3G), cocaine (Figure 3H),
or SE (Figure 3E)/RE (Figure 3F) pre-treated neurons found
robust staining of dendrites with Phalloidin/F-actin (green)
puncta and MAP-2 (blue) dendrites. These neurons exhibited
complex dendritic branching patterns and an extensive ﬁne
dendritic network. In contrast, examination of PHTPP pre-
treated SE/HIV-1 Tat + cocaine treated (Figure 3I), PHTPP
pre-treated RE/HIV-1 Tat + cocaine treated (Figure 3J), and
HIV-1 Tat + cocaine treated (Figure 3D) neurons found
reduced dendritic branching, diminished Phalloidin staining, and
dendritic fragmentation.
Discussion
Neurocognitive deﬁcits are more prevalent among HIV-1+
positive drug users (Nath, 2002; Levine et al., 2006; Devlin
et al., 2012; Weber et al., 2013). Cocaine is one of the
most commonly abused drugs in HIV-1+ individuals (Cook
et al., 2007; Korthuis et al., 2008), and has been shown to
potentiate neuronal death caused by HIV-1 proteins in vitro
(Kendall et al., 2005; Aksenov et al., 2006). Although neuronal
cell death is seen in HIV-1 (Li et al., 2005; Mattson et al.,
2005), synaptic dysfunction and loss are more predictive of
neurocognitive status (Ellis et al., 2007). We found (1) HIV-
1 Tat + cocaine exposure resulted in a signiﬁcant reduction
in F-actin rich puncta/synapses, relative to either HIV-1 Tat
or cocaine alone, (2) pre-treatment with either RE or SE
prevented the HIV-1 Tat + cocaine induced puncta/synaptic
loss, and (3) RE and SE provided synaptic protection from HIV-
1 Tat + cocaine exposure via an ERβ dependent mechanism.
These ﬁndings suggest that early treatment with RE or SE
may prevent the synaptopathy caused by HIV-1 and cocaine
abuse.
Cocaine potentiated the eﬀects of HIV-1 Tat at doses in
which HIV-1 Tat alone was not damaging to synaptic structures.
The dose of HIV-1 Tat was fourfold lower than concentrations
previously shown to cause neuronal death in similar neuronal
cell cultures (Kendall et al., 2005). The dose of cocaine reﬂected
physiological arterial levels observed in IV cocaine users (Evans
et al., 1996) and rats (Mactutus et al., 1994; Booze et al.,
1997); well below the cocaine concentration known to produce
neuronal death in vitro (Bennett et al., 1993; Nassogne et al.,
1995). However, low doses of HIV-1 Tat + cocaine produced
synaptic loss at an early time point (24 h) prior to the time
previously reported for neuronal death (48 h; Bertrand et al.,
2014). HIV-1 Tat (Wallace et al., 2006; Ferris et al., 2009; Midde
et al., 2013) and cocaine (Ritz and Kuhar, 1993) both inhibit
dopamine transporter (DAT) function, increase oxidative stress
(Aksenov et al., 2006; Fitting et al., 2015), and thereby may
cause depolymerization of F-actin and a subsequent reduction of
F-actin rich puncta/synapses.
S-Equol is the active metabolite of the soy derived
phytoestrogen daidzein (Setchell and Cassidy, 1999; Jackson
et al., 2011), and daidzein has been proposed to be responsible
for the cognitive health beneﬁts of soy products (Setchell and
Cassidy, 1999; Lampe, 2009; Jackson et al., 2011). Daidzein is
metabolized into SE via two distinct steps by various bacteria
found in the gut of animals and humans (Setchell et al., 2005;
Jackson et al., 2011). In humans, daidzein supplementation
results in plasma concentrations of 8–20 ng/ml S-equol (see
review: Jackson et al., 2011). A low concentration of S- and RE
(33 nM) as well as the mid-range concentration of equol (50 nM)
are equivalent to plasma concentrations observed in humans
following supplementation (8 and 12 ng/ml, respectively);
hence, these doses were used to evaluate potential synaptic
protection. Both enantiomers achieve full synaptic protection
at physiologically relevant concentrations that were 20x lower
than that of daidzein required for full protection (Bertrand
et al., 2014). Neurons pre-treated with daidzein and exposed
to a neurotoxic concentration of HIV-1 Tat protein were able
to not only maintain, but also restore lost synapses (Bertrand
et al., 2014); together, these results and those in the present
study, suggest that SE may be a potent aid in the prevention and
restoration of synaptic loss.
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FIGURE 3 | R-Equol and SE prevented HIV-1 Tat + cocaine synaptic loss via a selective estrogen receptor (ERβ) dependent mechanism. Cortical
neurons were pre-treated for 1 h with either MPP (ERα), PHTPP (ERβ), or G15 (GPR30) prior to treatment with either RE (A) or SE (B) to identify which specific ER
subtype was necessary for equol-mediated synaptic protection from HIV-1 Tat + cocaine. We found that pre-treatment with PHTPP (ERβ) inhibited both the RE
(panel A) and SE (panel B) induced synaptic protection in HIV-1 Tat + cocaine treated cortical neurons. (A) HIV-1 Tat + cocaine exposed neurons pre-treated with
either MPP or G15, and subsequently RE, had normal levels of dendritic F-actin puncta (i.e., not significantly different from vehicle-treated controls, p > 0.05). In
contrast, PHTPP-treated neurons had a significant loss of dendritic F-actin puncta compared to controls (p ≤ 0.05) and were not significantly different from HIV-1
Tat + cocaine treated dendrites (p > 0.05), indicating that PHTPP inhibited RE-induced synaptic protection. Mean ± SEM, ∗p ≤ 0.05. (B) HIV-1 Tat + cocaine
exposed neurons pre-treated with either MPP or G15, and subsequently SE, had normal levels of dendritic F-actin puncta (i.e., not significantly different from
vehicle-treated controls, p > 0.05). In contrast, PHTPP-treated neurons had a significant loss of dendritic F-actin puncta compared to controls (p ≤ 0.05) and were
not significantly different from HIV-1 Tat + cocaine treated dendrites (p > 0.05), indicating that PHTPP inhibited SE-induced synaptic protection. Mean ± SEM,
∗p ≤ 0.05. (C–J) The ERβ antagonist PHTPP significantly blocked equol-mediated protection from HIV-1 Tat + cocaine in cortical neurons. PHTPP pre-treated,
SE(I)/RE(J) treated, neurons lacked a fine dendritic network and had reduced dendritic branching, similar characteristics to those in non pre-treated
HIV-1Tat + cocaine neurons (D). In contrast, vehicle (C), HIV-1 Tat (10 nM; G), cocaine (H), and SE(E)/RE(F) treated neurons had robust dendrites with complex
branching patterns and a lack of aberrant morphology such as bundling or beading. Phalloidin/F-actin(green) and MAP-2 (blue); 20× magnification.
Both equol enantiomers prevented HIV-1 Tat-induced
(50 nM) and HIV-1 Tat (10 nM) + cocaine induced synaptic
loss. TMX pre-treatment blocked the neuroprotective actions of
both RE and SE, indicating that equol mediated neuroprotection
was via an estrogen receptor dependent mechanism. SE is a
potent ER agonist, with preferential binding to ERβ over ERα
(Setchell et al., 2005; Lampe, 2009; Jackson et al., 2011). In
order to determine the mechanism of both S- and RE synaptic
protection, the compounds MPP, PHTPP, and G15 (ERα, ERβ,
and GPR30 antagonists, respectively) were used to determine
which ER subtype mediated the neuroprotective eﬀects of SE and
RE. Only PHTPP blocked the neuroprotective eﬀects of SE and
RE, indicating that both enantiomers provide synaptic protection
via an ERβ dependent mechanism.
Our prior studies have found that treatment with 17β-estradiol
mitigates interactions between HIV-1 Tat protein and cocaine,
thereby preventing neuronal cell death in an ER dependent
manner (Kendall et al., 2005). Treatment with 17β-estradiol
suppresses HIV-1 Tat enhancement of LTR promoter activity in
astrocytes (Wilson et al., 2006). Over expression of ERα prevents
17β-estradiol mediated suppression of Tat-LTR promoter activity
in astrocytes (Heron et al., 2009). Unfortunately, activation of
the ERα subtype may lead to unwanted side eﬀects, limiting the
use of speciﬁc agonists which act at ERα receptors. We reported
estrogenic activation of the ERβ prevented HIV-1 Tat-induced
apoptosis (Adams et al., 2010, 2012), and the present ﬁndings
suggest ERβ is necessary for synaptic protection following HIV-
1 Tat and cocaine. Thus, an ERβ speciﬁc compound (i.e., SE
or other compounds), may be beneﬁcial for both preventing
HIV-1 synaptopathy, although the functional consequences of
ERβ speciﬁc compounds in HIV-1 therapeutics remains to be
determined.
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The gut-brain axis is a new area of study which recognizes
the bidirectional communication between the gut microbiota and
behavior (Cryan and Dinan, 2012; Foster and McVey Neufeld,
2013). SE is produced by the gut microbiota in humans and
animals, but not all humans are SE producers. Up to 80% of
individuals in China, Japan, and Korea are capable of producing
SE (Morton et al., 2002; Fujimoto et al., 2008), however, only 25%
of the population that consumes a Western diet are SE producers
(Lampe et al., 1998). It is currently unknown how HIV-1 may
aﬀect the gut microbiota, however, it may play an important role
in mediating disease progression as well as the neurocognitive
correlates of HIV-1. The ability of the gut metabolite SE to
alter the synaptopathy induced either by HIV-1 Tat alone, or
HIV-1 Tat and cocaine in combination, suggests that the gut
microbiota could play an important role in modulating CNS
health in HIV-1.
HIV-1 protein Tat in combination with cocaine resulted in
signiﬁcant loss of synapses; loss which may play a role in the
increased prevalence of HAND in cocaine users (Nath, 2010;
Purohit et al., 2011). Cognitive function in HAND is closely
correlated with synaptodendritic injury (Ellis et al., 2007), and
a reduction in synapses represents a potential mechanism for
the increased prevalence of HAND in HIV-1+ cocaine users
(Martin-Thormeyer and Paul, 2009; Nath, 2010; Gill and Kolson,
2014). HIV-1 Tat + cocaine synaptopathy occurs prior to overt
neuronal death (Kim et al., 2008; Bertrand et al., 2013, 2014),
and the synaptopathy is potentially reversible (Bertrand et al.,
2014), highlighting the importance of compounds, like SE, that
may oﬀer synaptic protection and restoration of normal synaptic
connectivity. Interestingly, we found that the synaptic protective
actions of equol may be mediated by an ERβ-dependent
mechanism. Equol actions targeted to the ERβ may limit
unwanted side-eﬀects, yet still provide neuroprotection at a
level similar to the eﬀects of 17β-estradiol (Kendall et al., 2005;
Simpkins and Singh, 2008; Adams et al., 2010; Simpkins et al.,
2012). SE is more potent than the parent compound daidzein
(Adams et al., 2012; Bertrand et al., 2014), suggesting that either
direct treatment with SE or treatment via gut metabolism of
daidzein may promote synaptic complexity following HIV-1 Tat
or Tat + cocaine exposure. Overall, the present data suggest
that ERβ may be a novel therapeutic target for the treatment
of HAND + drug abuse synaptopathy and early therapeutic
intervention with SE may prevent HIV-1 synaptopathy and
potentially delay the development of HAND.
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